The Giant in Oncology Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 presenting “Unanswered Questions” in Bispecifics with Aaron Goodman - “Papa Heme” & Dr. Bishop as panelists.
#HOPLive24 right here in Chicago.
Naveen Pemmaraju, MD Vincent Rajkumar Sanam Loghavi, MD صنم لغوی 🔬🧬 Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Joseph Mikhael Mikkael A. Sekeres MD, MS Mehdi Hamadani, MD Alan Skarbnik

⏰ It's time for the #bispecifics panel at #HOPLive24 !

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Michael R Bishop Aaron Goodman - “Papa Heme”

buff.ly/3xNw3wF

Proposed “Unanswered Questions” in Bispecifics as told by Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 to be debated and discussed by Aaron Goodman - “Papa Heme” & Dr. Bishop.
#HOPLive24 annual meeting.

Great discussion.

Rare moment when he is not tweeting Aaron Goodman - “Papa Heme” Amalia Aleck attending the #HOPLive24

How to manage toxicities of Bispecifics?
Answered or unanswered question Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

Session 2 on bispecifics #HOPLive24

he will be in Chicago at the First annual #HemOnc Pulse LIVE #HOPLive24 amongst faculty tackling 'Unanswered Questions' in Heme Cancers. Aaron Goodman - “Papa Heme” will be a panelist on the Bispecifics & Myeloma sessions & expect fireworks - he is also MOC-ready. Blood Cancers Today
Stay tuned

#Bispecifics in DLBCL: When & how?
In earlier lines?
In combination?
Combined with chemo vs other immunotherapy?
Diff Ag targets?
Ag loss?
T cell exhaustion
Randomised studies req re impact on PFS/OS
CRS management strategies better defined
Lorenzo Falchi
#MSKlymphomaCME

Comparison of CAR T-cell vs. bispecific Ab as 3rd(+) line DLBCL Rx: A Meta-analysis

16 studies: 1,347 pts in pooled analysis

•CAR-T: superior efficacy: ⬆️CR & pooled 1yr PFS cf bispecifics
but
•CAR-T exhibits ⬆️ incidence ≥G3 AEs cf bispecifics

ashpublications.org/blood/article/…

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Michael R Bishop Aaron Goodman - “Papa Heme” Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 outlines unanswered questions in #bispecifics :

✅ Efficacy of CAR-T versus bispecifics
✅ Safety
✅ Sequencing and timing
✅ Resistance
✅ Logistics and value

#HOPLive24

Fantastic talk Soni Smith MD ‘clinical adv & challenges in #FL ’
Many aspects inc ‘Is it curable?’

Rx naive
Role of maintenance? (GALLIUM update still no ⬆️OS)

R/R
Bispecifics: Mosun, Epco
#CAR -T (ELARA, ZUMA-5 in 3L+, TRANSCEND 2L/3L+)
Len
BTK-?
Role of ASCT?
#MSKlymphomaCME

Crucial reading for UK myeloma-ologists, hopefully we will have access to BCMA bispecifics at least by end June …

Better to invest in CD19 mAbs or bispecifics.

We cordially invite you to attend a symposium on July 27th that centers around CAR-T and Bispecifics. This event aims to engage with community oncologists and exchange ideas on the obstacles they encounter in their practice. We would be honored to have your valued participation…

No doubt, a helpful guide for managing #myeloma therapy in this ever-changing treatment landscape. #MMsm International Myeloma Foundation #Bispecifics

Aaron Goodman - “Papa Heme” on deciding between bispecifics versus CAR-T for patients with #myeloma :

'A lot of it depends on where they live, what they value,' he said. 'A far as efficacy, we don't know what’s better—bispecifics or CAR-T.'

#HOPLive24

How many CD19 bispecifics or mAbs in development. $cgem $elym 🤔

“Unanswered Questions” in Heme Cancers.
#HOPLive24 .
CART; Bispecifics; MDS; MPN; AML; ALL; HL; DLBCL; T-NHL; MM; CLL; CML; & more.

All happ Fri/Sat in Chicago. Thx 2 all faculty Sanam Loghavi, MD صنم لغوی 🔬🧬 Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Vincent Rajkumar Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Sangeetha Venugopal MD,MS Andrew M. Evens, DO, MBA, MSc Mehdi Hamadani, MD Ruben A. Mesa, MD Naveen Pemmaraju, MD

👏 We're only a few days away from #HOPLive24 !

🎙️ Whether you're looking forward to the #bispecifics panel with Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽, Michael R Bishop, & Aaron Goodman - “Papa Heme”, or the #AML panel with Naval Daver, M.D. & Mikkael A. Sekeres MD, MS, there's lots in store!

🙌 Learn more: buff.ly/3xNw3wF

Biotech Bois Look at the data from AK104.

My recollection is that Keytruda had about a 8% ORR in recurrent cervical cancer.

Akeso ASCO 2022 results were +70% ORR

This AK104 is part of next gen IgG-1 PD-1 bispecifics

molecules already late stage/approved abroad!

ascopubs.org/doi/10.1200/JC…

Nitin Jain, MD Challenging case involving advanced B-cell lymphoblastic leukemia (BLL) from the CAR-T and Bispecifics Conference [2024] oncologytube.com/nitin-jain-md-… Nitin Jain MD Anderson Cancer Center MD Education @Ryan_fitzpatric